HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Faisal Bakaeen David Rice Garrett L. Walsh Ara A. Vaporciyan Stephen G. Swisher Jack A. Roth Danny Chu Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bakaeen, F. Articles by Smythe, W. R. Search for Related Content PubMed PubMed Citation Articles by Bakaeen, F. Articles by Smythe, W. R. Related Collections Lung - cancer Related Article

Ann Thorac Surg 2007;84:982-986
© 2007 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Use of Aprotinin in Extrapleural Pneumonectomy: Effect on Hemostasis and Incidence of Complications

The University of Texas, MD Anderson Cancer Center, Houston, Texas

Accepted for publication March 19, 2007.

^_* Address correspondence to Dr Bakaeen, Michael E. DeBakey Veterans Affairs Medical Center, 2002 Holcombe Blvd, OCL (112), Houston, TX 77030 (Email: fbakaeen{at}bcm.edu).

Background: The purpose of this study was to examine the effect of aprotinin on blood loss in extrapleural pneumonectomy and to identify potential treatment-related complications.

Methods: Between March 1, 1999, and July 1, 2004, 27 (52%) of 52 patients who underwent extrapleural pneumonectomy received half-dose aprotinin (1 million kallikrein inhibition units load; 250,000 kallikrein inhibition units per hour infusion). A retrospective data review and analysis were performed.

Results: The mean age was 59.8 ± 11 years, and 45 of 52 patients (87%) were male. Indications for extrapleural pneumonectomy were malignant pleural mesothelioma (n = 50) and pleural-based sarcoma (n = 2). The administration of aprotinin had no significant effect on intraoperative blood loss (1,010 ± 599 versus 1,182 ± 688 mL; p = 0.34) or units of packed red blood cells transfused intraoperatively (2.0 ± 1.7 versus 1.9 ± 1.7 units; p = 0.86). None of the patients who received aprotinin required the use of non–packed red blood cells blood products, but 4 patients (16%) who did not receive aprotinin required such transfusion (p < 0.05). Postoperative chest tube output at 12 and 24 hours was lower in the aprotinin group (381 ± 195 and 867 ± 313 mL, respectively) compared with the control group (725 ± 527 and 1,221 ± 442 mL, respectively; p < 0.03). There was no significant difference in incidence of postoperative thromboembolic events between the aprotinin and the control group (5 versus 4 patients; p = 1.0), and 2 patients in each group experienced renal insufficiency (p = 1.0).

Conclusions: Half-dose aprotinin did not decrease intraoperative blood loss or packed red blood cells transfusion in extrapleural pneumonectomy. However, use of aprotinin was associated with decreased use of non–packed red blood cells blood products and lower postoperative chest tube output. Aprotinin administration was not associated with an increase in incidence of postoperative complications.

Related Article

Invited commentary

Jerrold H. Levy and Seth Force
Ann. Thorac. Surg. 2007 84: 986-987. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				F. G. Bakaeen and D. Rice Reply. Ann. Thorac. Surg., July 1, 2008; 86(1): 355 - 355. [Full Text] [PDF]

				D. West and D. Prakash Aprotinin and extrapleural pneumonectomy. Ann. Thorac. Surg., July 1, 2008; 86(1): 354 - 355. [Full Text] [PDF]

				J. H. Levy and S. Force Invited commentary Ann. Thorac. Surg., September 1, 2007; 84(3): 986 - 987. [Full Text] [PDF]